STOCK TITAN

Talaris Therapeutics to Participate in Two Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

BOSTON and LOUISVILLE Ky., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that members of its senior management team will participate in the following investor conferences:

Morgan Stanley 20th Annual Global Healthcare Conference
Fireside chat date: Monday, September 12, 2022
Fireside chat time: 1:40 p.m. ET
Location: Sheraton Hotel, New York, NY

H.C. Wainwright 24th Annual Global Investment Conference
Presentation date: Wednesday, September 14, 2022
Presentation time: 9:00 a.m. ET
Location: Lotte New York Palace Hotel, New York, NY

A live webcast of the presentations will be available on the investors section of the Talaris website at www.talaristx.com. After the live webcast, a replay of the events can be found on the Talaris website.

About Talaris Therapeutics
Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders. Talaris maintains corporate offices in Boston, MA, its cell processing facility in Louisville, KY, and additional research operations in Houston, TX.

Media Contact
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783

Investor Contact
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
(339) 970-2843


Talaris Therapeutics, Inc.

NASDAQ:TALS

TALS Rankings

TALS Latest News

TALS Stock Data

119.57M
4.21M
11.91%
77.66%
0.77%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link

About TALS

talaris therapeutics is a late-clinical stage biotechnology company based in boston, ma and louisville, ky. talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. the company was founded on technology discovered and developed by dr. suzanne ildstad and operates its own cell processing facility in louisville. talaris is backed by leading life sciences investors blackstone life sciences, longitude capital and qiming venture partners usa.